SCHEMBL7220712

SCHEMBL7220712

COC(=O)[C@@H]1CCCCN1S(=O)(=O)Nc1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.61
FKBP1A P62942 6/20 0.57
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
USP2 O75604 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
SLC2A1 P11166 1/20 0.43
CASP3 P42574 1/20 0.42
FKBP5 Q13451 1/20 0.41
LMNA P02545 2/20 0.41
THRB P10828 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220717 1.00 L3MBTL1 (0.61) L3MBTL1FKBP1AALDH1A1MAPTUSP2
SCHEMBL7221488 0.91 L3MBTL1 (0.61) L3MBTL1FKBP1AALDH1A1MAPTUSP2
SCHEMBL7221476 0.91 L3MBTL1 (0.61) L3MBTL1FKBP1AALDH1A1MAPTUSP2
SCHEMBL7220517 0.85 FKBP1A (0.59) L3MBTL1FKBP1A
SCHEMBL7506812 0.85 FKBP1A (0.59) L3MBTL1FKBP1A
SCHEMBL7222585 0.83 L3MBTL1 (0.51) L3MBTL1FKBP1AALDH1A1MAPTUSP2
SCHEMBL7221192 0.81 FKBP1A (0.55) L3MBTL1FKBP1AALDH1A1KMT2ANPSR1
SCHEMBL7220384 0.81 FKBP1A (0.69) FKBP1A
SCHEMBL7507953 0.81 FKBP1A (0.69) FKBP1A
SCHEMBL7228073 0.80 SLC29A1 (0.52) L3MBTL1FKBP1AALDH1A1HSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6544987-B2 Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders PFIZER INC. 2003-04-08 US disclosed
EP-1237869-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION AGOURON PHARMACEUTICALS, INC. (US) 2002-09-11 EP disclosed
US-20020061881-A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation AGOURON PHARMACEUTICALS, INC. 2002-05-23 US disclosed
WO-2001040185-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION AGOURON PHARMACEUTICALS, INC. (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061881-A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation NGF, GAP43, BDNF L3MBTL1 4040/4885FKBP1A 4192/4885ALDH1A1 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.